SHANGHAI, Sept. 5, 2024 /PRNewswire/ -- UltraDx Bio is proud to announce that its flagship product, the UD-X™ Fully Automated Single-Molecule Array Fluorescence Immunoassay Analyzer, has received its first clinical registration approval in China. This groundbreaking achievement is now officially listed on the National Medical Products Administration (NMPA) website (Registration Certificate No.: JXZZ 20242220334) and marks a significant milestone in the field of medical diagnostics. The UD-X™ Single-Molecule Analyzer is designed for the ultra-sensitive detection and quantification of trace protein biomarkers in body fluids, reaching sensitivity levels at the fg/ml scale. This technology will be utilized alongside soon-to-be-approved companion assay kits, addressing the precision detection needs of clinical diagnostics and community health screenings.
The successful approval and clinical deployment of the UD-X™ Single-Molecule Analyzer are poised to revolutionize early screening, early diagnosis, companion diagnosis and treatment effectiveness evaluation for diseases such as Alzheimer's Disease (AD). This advancement is not only of immense clinical value but also holds significant social and economic importance.
Register to read this story and more for free.
Signing up for an account helps us improve your browsing experience.
ContinueOR
See our subscription options.